- Home
- SABS vs BIAF Comparison
SABS vs BIAF Comparison
Compare SABS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- BIAF
- Stock Information
- Founded
- SABS 2014
- BIAF 2014
- Country
- SABS United States
- BIAF United States
- Employees
- SABS N/A
- BIAF N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SABS Health Care
- BIAF Health Care
- Exchange
- SABS Nasdaq
- BIAF Nasdaq
- Market Cap
- SABS 11.4M
- BIAF 12.2M
- IPO Year
- SABS N/A
- BIAF 2022
- Fundamental
- Price
- SABS $1.37
- BIAF $0.49
- Analyst Decision
- SABS Strong Buy
- BIAF Hold
- Analyst Count
- SABS 5
- BIAF 1
- Target Price
- SABS $11.40
- BIAF N/A
- AVG Volume (30 Days)
- SABS 25.6K
- BIAF 28.5M
- Earning Date
- SABS 05-19-2025
- BIAF 05-14-2025
- Dividend Yield
- SABS N/A
- BIAF N/A
- EPS Growth
- SABS N/A
- BIAF N/A
- EPS
- SABS N/A
- BIAF N/A
- Revenue
- SABS $1,322,410.00
- BIAF $9,362,022.00
- Revenue This Year
- SABS N/A
- BIAF N/A
- Revenue Next Year
- SABS $50.00
- BIAF $19.99
- P/E Ratio
- SABS N/A
- BIAF N/A
- Revenue Growth
- SABS N/A
- BIAF 269.68
- 52 Week Low
- SABS $1.00
- BIAF $0.24
- 52 Week High
- SABS $5.01
- BIAF $3.16
- Technical
- Relative Strength Index (RSI)
- SABS 46.90
- BIAF 48.21
- Support Level
- SABS $1.30
- BIAF $0.46
- Resistance Level
- SABS $1.49
- BIAF $0.58
- Average True Range (ATR)
- SABS 0.13
- BIAF 0.11
- MACD
- SABS 0.04
- BIAF -0.01
- Stochastic Oscillator
- SABS 75.51
- BIAF 8.65
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.